Skip to main content

Advertisement

SpringerLink
Log in

Expression and clinical significance of organic cation transporter family in glioblastoma multiforme

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

Solute carrier (SLC) 22 A1, A2, and A3 are polyspecific transporters transporting organic cations like histamine, serotonin, norepinephrine, dopamine, MPP + , and toxins. The expression of SLC22A1–A3 in cancer is seldom investigated, and the function of SLC22A1–A3 in glioblastoma multiforme (GBM) is never elucidated.

Materials

In our study, we detected the expression of SLC22A1–A3 in 11 fresh GBMs and tumor-adjacent brain tissues with qPCR, and in 129 paraffin-embedded GBMs with immunohistochemistry (IHC). With chi-square test, we investigated the correlation between expression of SLC22A1–A3 and the clinicopathological factors including patients’ age, sex, tumor size, and KPS score. With Kaplan–Meier method and Cox-regression model, we estimated the prognostic significance of SLC22A1–A3 in GBM.

Results

SLC22A3 was significantly downregulated in GBMs compared with the tumor-adjacent normal tissues. With univariate survival analyses, we showed that SLC22A3, instead of SLC22A1 and A2, was an independent biomarker predicting favorable prognosis. With multivariate analyses, SLC22A3 was identified as an independent prognostic biomarker indicating the favorable outcome of GBM.

Conclusions

SLC22A3 is an independent favorable prognostic biomarker of GBM. Patients with low SLC22A3 may be more high-risk and should receive more intensive post-operational supervision and treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507

    Article  CAS  Google Scholar 

  2. Ostrom QT, Gittleman H, Fulop J et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-oncology 17 Suppl 4: iv1-iv62

  3. Dong C, Fan W, Fang S (2020) PBK as a potential biomarker associated with prognosis of glioblastoma. J Mol Neurosci : MN 70:56–64

    Article  CAS  Google Scholar 

  4. Lee EQ, Muzikansky A, Drappatz J et al (2016) A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro Oncol 18:849–854

    Article  CAS  Google Scholar 

  5. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466

    Article  CAS  Google Scholar 

  6. Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110

    Article  CAS  Google Scholar 

  7. Roth M, Obaidat A, Hagenbuch B (2012) OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 165:1260–1287

    Article  CAS  Google Scholar 

  8. Koepsell H, Endou H (2004) The SLC22 drug transporter family. Pflugers Arch 447:666–676

    Article  CAS  Google Scholar 

  9. Liu X (2019) SLC family transporters. Adv Exp Med Biol 1141:101–202

    Article  CAS  Google Scholar 

  10. Sweet DH (2005) Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl Pharmacol 204:198–215

    Article  CAS  Google Scholar 

  11. Hsu CM, Lin PM, Chang JG et al (2017) Upregulated SLC22A3 has a potential for improving survival of patients with head and neck squamous cell carcinoma receiving cisplatin treatment. Oncotarget 8:74348–74358

    Article  Google Scholar 

  12. Herraez E, Lozano E, Macias RI et al (2013) Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology 58:1065–1073

    Article  CAS  Google Scholar 

  13. Lautem A, Heise M, Grasel A et al (2013) Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. Int J Oncol 42:1297–1304

    Article  CAS  Google Scholar 

  14. Du K, Wu X, Ji X et al (2020) Early growth response 1 promoted the invasion of glioblastoma multiforme by elevating HMGB1. J Neuro Sci

  15. Zhao B, Sun J, Du K, Liang N (2020) Sprouty 4 suppresses glioblastoma invasion by inhibiting ERK phosphorylation and ETS-1-induced matrix metalloproteinase-9. J Neuro Sci

  16. Chen T, Li K, Liu Z et al (2021) WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1alpha accumulation in Myc-dependent and independent pathways. Mol ther : the journal of the American Society of Gene Therapy 

  17. Kolz C, Schaeffeler E, Schwab M, Nies AT (2021) Genetic and epigenetic regulation of organic cation transporters. Handb Exp Pharmacol

  18. Schaeffeler E, Hellerbrand C, Nies AT et al (2011) DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome medicine 3:82

    Article  CAS  Google Scholar 

  19. Tomlins SA, Mehra R, Rhodes DR et al (2007) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39:41–51

    Article  CAS  Google Scholar 

  20. Ren A, Sun S, Li S et al (2019) Genetic variants in SLC22A3 contribute to the susceptibility to colorectal cancer. Int J Cancer 145:154–163

    Article  CAS  Google Scholar 

  21. Heise M, Lautem A, Knapstein J et al (2012) Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer 12:109

    Article  CAS  Google Scholar 

  22. Cervenkova L, Vycital O, Bruha J et al (2019) Protein expression of ABCC2 and SLC22A3 associates with prognosis of pancreatic adenocarcinoma. Sci Rep 9:19782

    Article  CAS  Google Scholar 

  23. Mohelnikova-Duchonova B, Brynychova V, Hlavac V et al (2013) The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. Cancer Chemother Pharmacol 72:669–682

    Article  CAS  Google Scholar 

  24. Wu X, Huang W, Ganapathy ME et al (2000) Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol 279:F449-458

    Article  CAS  Google Scholar 

  25. Amphoux A, Vialou V, Drescher E et al (2006) Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 50: 941–952

  26. Grundemann D, Schechinger B, Rappold GA, Schomig E (1998) Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci 1:349–351

    Article  CAS  Google Scholar 

  27. Pavlidis N, Kalef-Ezra J, Briassoulis E et al (1994) Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol 22:162–167

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Shandong Second Provincial General Hospital, Shandong Second Provincial ENT Hospital, 4 Duanxingxi Road, Jinan, 250022, Shandong, China

    Qingbei Lian, Shiling Xiao & Didong Xie

  2. Shandong Academy of Medical Sciences, Shandong First Medical University, Tai’an, China

    Yunda Wang & Haocong Wang

Authors
  1. Qingbei Lian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shiling Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yunda Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Haocong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Didong Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Didong Xie.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lian, Q., Xiao, S., Wang, Y. et al. Expression and clinical significance of organic cation transporter family in glioblastoma multiforme. Ir J Med Sci 191, 1115–1121 (2022). https://doi.org/10.1007/s11845-021-02675-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-021-02675-3

Keywords

Search

Navigation